Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458612 | 0.88 | SLC22A12 (0.58) | HSD17B2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL31215352 | 0.85 | CA12 (0.59) | TSHRSMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL457531 | 0.85 | CA12 (0.59) | TSHRSMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL12493963 | 0.85 | ALDH1A1 (0.51) | MAPTMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL459946 | 0.85 | HSD17B2 (0.47) | HSD17B2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL12494360 | 0.83 | SMPD1 (0.50) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL30506315 | 0.82 | HSD17B2 (0.76) | HSD17B2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL1660365 | 0.82 | HSD17B2 (0.76) | HSD17B2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL458099 | 0.81 | ALDH1A1 (0.51) | HSD17B2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL2088933 | 0.80 | KMT2A (0.53) | MAPTMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | PHARMA CINQ, LLC | 2017-02-16 | — | — | US | disclosed |
| EP-2282736-B1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORP (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8889724-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130336949-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130331452-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-12-12 | — | — | US | disclosed |
| US-8410154-B2 | Tetrazole compounds for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| WO-2012033720-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2282736-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009134995-A2 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085957-B2 | Benzoic acid compounds for reducing uric acid | FPR1, FFAR1, GLS | HSD17B2 2561/4885MAPT 3075/4885MEN1 2767/4885 |
| US-20130336949-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | GLS, CASP1, PCSK9 | HSD17B2 1534/4885MAPT 147/4885MEN1 931/4885 |
| US-20130331452-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | GLS, NLRP3, XDH | HSD17B2 2954/4885MAPT 1030/4885MEN1 1444/4885 |
| US-20110206653-A1 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID | FPR1, CASP1, PON1 | HSD17B2 1414/4885MAPT 1001/4885MEN1 1832/4885 |
| US-20170042844-A1 | BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID | FPR1, FFAR1, GLS | HSD17B2 2561/4885MAPT 3075/4885MEN1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.